Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Breast Cancer

A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle

Bone Marrow Transplantation volume 25, pages 519–524 (2000)Cite this article

Abstract

Multi-cycle high-dose chemotherapy with autologous stem cell support (HDC-ASCS) may improve the results obtained with single-cycle HDC-ASCS in metastatic breast cancer (MBC). However, the tolerability and efficacy of additional cycles of HDC-ASCS in patients selected using standard eligibility criteria for single cycle HDC-ASCS is uncertain. Twenty-nine patients with MBC and a CR or PR to induction chemotherapy were selected by standard institutional eligibility criteria for single-cycle HDC-ASCS. Cycle 1 HDC-ASCS (cyclophosphamide 6 g/m2; mitoxantrone 70 mg/m2; carboplatin 800 mg/m2) was followed by a planned second cycle (etoposide 1.6 g/m2; thiotepa 800 mg/m2; carboplatin 800 mg/m2 modulated by tamoxifen 120 mg/m2/day × 5 days) with a median interval of 3.2 months. CR rate was 20% after induction chemotherapy and 33% and 54% after HDC cycles I and II, respectively. Sixteen patients (55%) failed to complete HDC cycle II within 200 days because of disease progression, toxicity, inadequate stem cell collection, insurance denials or patient choice. Median progression-free survival (PFS) for all 29 patients entered is 301 days from date of HDC cycle I and actuarial PFS at 2 years is 35%. For the 13 patients who received the two cycles of HDC-ASCS, actuarial PFS at 2 years was 54% (P = NS compared to those receiving only one cycle). These data show that a second cycle of full-dose intensity HDC-ASCS may increase the proportion of patients with MBC that achieve CR and may increase PFS. However, a large proportion of patients that complete HDC-ASCS cycle I may fail to proceed to cycle II in a timely fashion. Bone Marrow Transplantation (2000) 25, 519–524.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Parker SL, Tong T, Bolden S et al. Cancer statistics 1997 CA Cancer J Clin 1997 47: 5–27

    Article  CAS  Google Scholar 

  2. Clark G, Sledge GW, Osborne CK et al. Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients J Clin Oncol 1987 5: 55–61

    Article  CAS  Google Scholar 

  3. Mick R, Begg CB, Antman K et al. Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies? Breast Cancer Res Treat 1989 13: 33–38

    Article  CAS  Google Scholar 

  4. Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer J Clin Oncol 1988 6: 1368–1376

    Article  CAS  Google Scholar 

  5. Vincent MD, Powles TJ, Coombes RC, McElwain TJ . Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy Cancer Chemother Pharmacol 1988 21: 255–260

    CAS  PubMed  Google Scholar 

  6. Williams SF, Mick R, Desser R et al. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer J Clin Oncol 1989 7: 1824–1830

    Article  CAS  Google Scholar 

  7. Dunphy FR, Spitzer G, Buzdar AU et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support J Clin Oncol 1990 8: 1207–1216

    Article  CAS  Google Scholar 

  8. Kennedy MJ, Beveridge RA, Rowley SD et al. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer J Natl Cancer Inst 1991 83: 920–926

    Article  CAS  Google Scholar 

  9. Williams SF, Gilewski T, Mick R, Bitran JD . High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report J Clin Oncol 1992 10: 1743–1747

    Article  CAS  Google Scholar 

  10. Antman KH, Rowlings PA, Vaughan WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America J Clin Oncol 1997 15: 1870–1879

    Article  CAS  Google Scholar 

  11. Bezwoda WR, Seymour L, Dansey RD . High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial (see comments) J Clin Oncol 1995 13: 2483–2489

    Article  CAS  Google Scholar 

  12. Rizzieri DA, Vredenburgh JJ, Chao NJ et al. Long-term disease-free survival for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose therapy with hematopoietic support Blood 1998 92: 323a

    Google Scholar 

  13. Norton L, Simon R . The Norton–Simon hypothesis revisited Cancer Treat Rep 1986 70: 163–169

    CAS  PubMed  Google Scholar 

  14. Philip T, Ladenstein R, Zucker JM et al. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study Br J Cancer 1993 67: 119–127

    Article  CAS  Google Scholar 

  15. Ayash LJ, Elias A, Wheeler C et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study J Clin Oncol 1994 12: 37–44

    Article  CAS  Google Scholar 

  16. Bitran JD, Samuels B, Klein L et al. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer BoneMarrow Transplant 1996 17: 157–162

    CAS  Google Scholar 

  17. McClay EF, Albright KD, Jones JA et al. Tamoxifen modulation of cisplatin cytotoxicity in human malignancies Int J Cancer 1993 55: 1018–1022

    Article  CAS  Google Scholar 

  18. McClay EF, Albright KD, Jones JA et al. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines Br J Cancer 1994 70: 449–452

    Article  CAS  Google Scholar 

  19. McClay EF, McClay ME, Jones JA et al. A phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma Cancer 1997 79: 1037–1043

    Article  CAS  Google Scholar 

  20. Crown J, Norton L . Potential strategies for improving the results of high-dose chemotherapy in patients with metastatic breast cancer Ann Oncol 1995 6: 21–26

    Article  Google Scholar 

  21. Ayash LJ, Elias A, Schwartz G et al. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin J Clin Oncol 1996 14: 2984–2992

    Article  CAS  Google Scholar 

  22. Ghalie R, Williams S, Valentino LA et al. Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer Biol Blood Marrow Transplant 1995 1: 40–46

    CAS  PubMed  Google Scholar 

  23. Honkoop AH, van der Wall E, Feller N et al. Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer (see comments) Ann Oncol 1997 8: 957–962

    Article  CAS  Google Scholar 

  24. Viens P, Gravis G, Genre D et al. High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer Bone Marrow Transplant 1997 20: 199–203

    Article  CAS  Google Scholar 

  25. Danova M, Perotti C, Mora O et al. Multicyclic dose-intensive chemotherapy with circulating progenitor cell support for high-risk primary breast cancer Oncol Rep 1998 5: 427–429

    CAS  PubMed  Google Scholar 

  26. Hohaus S, Wallwiener D, Martin S et al. Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer Semin Oncol 1998 25: (Suppl. 4) 7–11; Discussion 45–48

    Google Scholar 

Download references

Author information

Author notes

  1. AD Ho

    Present address: Department of Medicine V, University of Heidelberg, Heidelberg, Germany

Authors and Affiliations

  1. Blood and Marrow Transplantation Program, University of California, San Diego, La Jolla, CA, USA

    A Bashey, S Corringham, J Garrett, TA Lane, EA Gilpin, RET Corringham, P Law & AD Ho

Authors
  1. A Bashey
    View author publications

    Search author on:PubMed Google Scholar

  2. S Corringham
    View author publications

    Search author on:PubMed Google Scholar

  3. J Garrett
    View author publications

    Search author on:PubMed Google Scholar

  4. TA Lane
    View author publications

    Search author on:PubMed Google Scholar

  5. EA Gilpin
    View author publications

    Search author on:PubMed Google Scholar

  6. RET Corringham
    View author publications

    Search author on:PubMed Google Scholar

  7. P Law
    View author publications

    Search author on:PubMed Google Scholar

  8. AD Ho
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bashey, A., Corringham, S., Garrett, J. et al. A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle. Bone Marrow Transplant 25, 519–524 (2000). https://doi.org/10.1038/sj.bmt.1702172

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702172

Keywords

Search

Advanced search

Quick links